STAAR Surgical Q1 2026 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 41 minutes ago
0mins
Should l Buy STAA?
Source: seekingalpha
- Significant Sales Growth: In Q1 2026, STAAR Surgical reported net sales of $93.5 million, a remarkable 119.6% increase year-over-year, with $47.4 million coming from the Chinese market, indicating strong global performance and a recovery in sales, particularly in China.
- Improved Profitability: The adjusted EBITDA reached $24.4 million with a gross profit margin of 73.6%, reflecting substantial progress in cost control and profitability enhancement, although total operating expenses were $60.9 million, highlighting the need for ongoing cost management during expansion.
- EVO+ ICL Launch Progress: The successful launch of EVO+ ICL in China, with meaningful volumes shipped and inventory levels normalized to contractual targets, demonstrates the company's adaptability in new product promotion and market demand, which is expected to drive future sales growth.
- Cautious Future Outlook: While management remains optimistic about a $225 million spending target for 2026, they refrained from providing specific revenue guidance due to macroeconomic and geopolitical uncertainties, indicating a cautious approach to future market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STAA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STAA
Wall Street analysts forecast STAA stock price to rise
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 28.180
Low
30.75
Averages
30.75
High
30.75
Current: 28.180
Low
30.75
Averages
30.75
High
30.75
About STAA
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
STAAR Surgical Q1 2026 Earnings Call Highlights
- Significant Sales Growth: In Q1 2026, STAAR Surgical reported net sales of $93.5 million, a remarkable 119.6% increase year-over-year, with $47.4 million coming from the Chinese market, indicating strong global performance and a recovery in sales, particularly in China.
- Improved Profitability: The adjusted EBITDA reached $24.4 million with a gross profit margin of 73.6%, reflecting substantial progress in cost control and profitability enhancement, although total operating expenses were $60.9 million, highlighting the need for ongoing cost management during expansion.
- EVO+ ICL Launch Progress: The successful launch of EVO+ ICL in China, with meaningful volumes shipped and inventory levels normalized to contractual targets, demonstrates the company's adaptability in new product promotion and market demand, which is expected to drive future sales growth.
- Cautious Future Outlook: While management remains optimistic about a $225 million spending target for 2026, they refrained from providing specific revenue guidance due to macroeconomic and geopolitical uncertainties, indicating a cautious approach to future market conditions.
See More
STAAR Surgical Q1 Earnings Exceed Expectations
- Earnings Beat: STAAR Surgical reported a Q1 non-GAAP EPS of $0.48, surpassing expectations by $0.40, indicating a significant improvement in the company's profitability.
- Revenue Surge: Q1 revenue reached $93.5 million, a remarkable 119.5% year-over-year increase, exceeding market expectations by $14.78 million, reflecting rapid growth driven by strong market demand.
- Gross Margin Improvement: The gross margin improved from 65.8% a year ago to 73.6%, demonstrating significant progress in cost control and product pricing, thereby enhancing overall profitability.
- Net Income Recovery: The company achieved a net income of $5.2 million, or $0.10 per diluted share, compared to a net loss of $54.2 million a year ago, showcasing a substantial recovery in financial health.
See More
STAAR Surgical to Announce Q1 Earnings on May 13
- Earnings Announcement Schedule: STAAR Surgical (STAA) is set to release its Q1 earnings on May 13 after market close, with consensus EPS estimated at $0.08 and revenue projected at $78.72 million, reflecting an impressive 84.8% year-over-year growth, indicating strong market performance.
- Performance Expectation Analysis: Over the past year, STAAR Surgical has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, suggesting volatility in profitability that warrants cautious investor sentiment.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen six upward revisions with no downward adjustments, indicating analyst optimism about future profitability; however, revenue estimates have experienced one upward revision and four downward adjustments, reflecting concerns about sales growth.
- Market Reaction: Canaccord Genuity has upgraded STAAR Surgical to a “Buy” rating, which may drive stock price increases ahead of the earnings report, prompting investors to monitor the impact of the upcoming results on stock performance.
See More
STAAR Surgical to Release Q1 2026 Financial Results and Host Earnings Call
- Earnings Release Schedule: STAAR Surgical will release its Q1 2026 financial results on May 13, 2026, after market close, accompanied by a shareholder letter, demonstrating the company's commitment to financial transparency.
- Conference Call Details: The company will host a conference call at 5:30 PM ET on the same day to discuss financial results and business progress, expected to cover key strategic priorities such as revenue growth and profit expansion, reflecting STAAR's emphasis on investor communication.
- Market Dynamics Update: The call will focus on dynamics in key markets, including China, indicating STAAR's sensitivity to global market changes and its strategic positioning in international markets.
- Innovation and Development: Since 1982, STAAR has focused on ophthalmic surgery, selling over 4 million implantable lenses in 85 countries, showcasing its leadership in vision correction and ongoing commitment to innovation.
See More
Analysis of Small-Cap Stock Opportunities and Risks
- STAAR Surgical Performance Decline: STAAR Surgical, with a market cap of $1.32 billion, has seen a 13.8% revenue decline over the past two years as customers postponed purchases, indicating weak market demand that could hinder future growth potential.
- Deteriorating Cash Flow: The company's free cash flow margin has dropped by 29.9 percentage points over the last five years, suggesting that STAAR's capital-intensive operations are facing challenges in an increasingly competitive environment, which may lead to decreased investor confidence.
- Strong Growth for monday.com: monday.com, valued at $3.45 billion, has averaged 26.9% ARR growth, with its software considered mission-critical by customers, indicating strong market demand and customer stickiness, which may allow for continued market share expansion.
- Viper Energy's Clear Advantages: Viper Energy, with a market cap of $9.29 billion, has achieved a superb 34% annual revenue growth over the past decade, and its 100% gross margin along with a 5.4 percentage point EBITDA margin expansion demonstrate the company's competitive strength and profitability in resource extraction.
See More
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
- Mixed Market Performance: Late Thursday afternoon, healthcare stocks showed mixed results, with the NYSE Health Care Index rising by 0.1%, indicating a cautious market sentiment towards the healthcare sector amid economic uncertainties.
- Investor Sentiment Fluctuations: While the overall index saw a slight increase, individual healthcare stocks exhibited varied performances, influenced by company earnings reports and market dynamics, highlighting the volatility and uncertainty in investor sentiment.
- Uncertain Industry Outlook: The future of the healthcare industry faces challenges, particularly in light of changing policies and economic conditions, prompting investors to closely monitor potential impacts from regulatory changes on the sector.
- Long-Term Trends to Watch: Despite the mixed short-term performance of healthcare stocks, the sector is still viewed as having growth potential in the long run, driven by an aging population and increasing health demands.
See More
STAAR Surgical Q1 2026 Earnings Call Highlights
- Significant Sales Growth: In Q1 2026, STAAR Surgical reported net sales of $93.5 million, a remarkable 119.6% increase year-over-year, with $47.4 million coming from the Chinese market, indicating strong global performance and a recovery in sales, particularly in China.
- Improved Profitability: The adjusted EBITDA reached $24.4 million with a gross profit margin of 73.6%, reflecting substantial progress in cost control and profitability enhancement, although total operating expenses were $60.9 million, highlighting the need for ongoing cost management during expansion.
- EVO+ ICL Launch Progress: The successful launch of EVO+ ICL in China, with meaningful volumes shipped and inventory levels normalized to contractual targets, demonstrates the company's adaptability in new product promotion and market demand, which is expected to drive future sales growth.
- Cautious Future Outlook: While management remains optimistic about a $225 million spending target for 2026, they refrained from providing specific revenue guidance due to macroeconomic and geopolitical uncertainties, indicating a cautious approach to future market conditions.
See More
STAAR Surgical Q1 Earnings Exceed Expectations
- Earnings Beat: STAAR Surgical reported a Q1 non-GAAP EPS of $0.48, surpassing expectations by $0.40, indicating a significant improvement in the company's profitability.
- Revenue Surge: Q1 revenue reached $93.5 million, a remarkable 119.5% year-over-year increase, exceeding market expectations by $14.78 million, reflecting rapid growth driven by strong market demand.
- Gross Margin Improvement: The gross margin improved from 65.8% a year ago to 73.6%, demonstrating significant progress in cost control and product pricing, thereby enhancing overall profitability.
- Net Income Recovery: The company achieved a net income of $5.2 million, or $0.10 per diluted share, compared to a net loss of $54.2 million a year ago, showcasing a substantial recovery in financial health.
See More
STAAR Surgical to Announce Q1 Earnings on May 13
- Earnings Announcement Schedule: STAAR Surgical (STAA) is set to release its Q1 earnings on May 13 after market close, with consensus EPS estimated at $0.08 and revenue projected at $78.72 million, reflecting an impressive 84.8% year-over-year growth, indicating strong market performance.
- Performance Expectation Analysis: Over the past year, STAAR Surgical has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, suggesting volatility in profitability that warrants cautious investor sentiment.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen six upward revisions with no downward adjustments, indicating analyst optimism about future profitability; however, revenue estimates have experienced one upward revision and four downward adjustments, reflecting concerns about sales growth.
- Market Reaction: Canaccord Genuity has upgraded STAAR Surgical to a “Buy” rating, which may drive stock price increases ahead of the earnings report, prompting investors to monitor the impact of the upcoming results on stock performance.
See More
STAAR Surgical to Release Q1 2026 Financial Results and Host Earnings Call
- Earnings Release Schedule: STAAR Surgical will release its Q1 2026 financial results on May 13, 2026, after market close, accompanied by a shareholder letter, demonstrating the company's commitment to financial transparency.
- Conference Call Details: The company will host a conference call at 5:30 PM ET on the same day to discuss financial results and business progress, expected to cover key strategic priorities such as revenue growth and profit expansion, reflecting STAAR's emphasis on investor communication.
- Market Dynamics Update: The call will focus on dynamics in key markets, including China, indicating STAAR's sensitivity to global market changes and its strategic positioning in international markets.
- Innovation and Development: Since 1982, STAAR has focused on ophthalmic surgery, selling over 4 million implantable lenses in 85 countries, showcasing its leadership in vision correction and ongoing commitment to innovation.
See More
Analysis of Small-Cap Stock Opportunities and Risks
- STAAR Surgical Performance Decline: STAAR Surgical, with a market cap of $1.32 billion, has seen a 13.8% revenue decline over the past two years as customers postponed purchases, indicating weak market demand that could hinder future growth potential.
- Deteriorating Cash Flow: The company's free cash flow margin has dropped by 29.9 percentage points over the last five years, suggesting that STAAR's capital-intensive operations are facing challenges in an increasingly competitive environment, which may lead to decreased investor confidence.
- Strong Growth for monday.com: monday.com, valued at $3.45 billion, has averaged 26.9% ARR growth, with its software considered mission-critical by customers, indicating strong market demand and customer stickiness, which may allow for continued market share expansion.
- Viper Energy's Clear Advantages: Viper Energy, with a market cap of $9.29 billion, has achieved a superb 34% annual revenue growth over the past decade, and its 100% gross margin along with a 5.4 percentage point EBITDA margin expansion demonstrate the company's competitive strength and profitability in resource extraction.
See More
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
- Mixed Market Performance: Late Thursday afternoon, healthcare stocks showed mixed results, with the NYSE Health Care Index rising by 0.1%, indicating a cautious market sentiment towards the healthcare sector amid economic uncertainties.
- Investor Sentiment Fluctuations: While the overall index saw a slight increase, individual healthcare stocks exhibited varied performances, influenced by company earnings reports and market dynamics, highlighting the volatility and uncertainty in investor sentiment.
- Uncertain Industry Outlook: The future of the healthcare industry faces challenges, particularly in light of changing policies and economic conditions, prompting investors to closely monitor potential impacts from regulatory changes on the sector.
- Long-Term Trends to Watch: Despite the mixed short-term performance of healthcare stocks, the sector is still viewed as having growth potential in the long run, driven by an aging population and increasing health demands.
See More
